Expressing the Promise of Your Protein

Whether you are developing a Monoclonal Antibody, Recombinant Protein, Vaccine, or Antibody Drug Conjugate, you should consider Goodwin Biotechnology, Inc. (GBI) as your development partner.

Our Mission Statement

GBI is a world-class CMO that excels as a strategic partner to deliver the highest quality material from proof of concept through product for clinical trials by employing superior cGMP compliant services that enable cost-effective, on-time delivery of our client's pre-clinical and clinical supplies to enhance patient's lives.

Define Your Needs With GBI –
Your Single Source Solution™

GBI is dedicated to partnering with you on your project, whether you are:

A university or a medical institute involved in Translational Medicine
A start up or a large, multi-national biomedical / pharmaceutical firm developing a Innovative Protein or a Biosimilar.
An early stage or entrepreneurial company that needs help on a Cell Culture project or has a need for Bioconjugation
A university or company interested in developing a highly potent Cytotoxic Antibody Drug Conjugate

Our goal at GBI is to provide superior service to our clients that not only meets, but exceeds their expectations. We can be a one-stop shop or we can help determine where we can add the most value when you need us anywhere along the process:

Cell line development from cDNA
Proof of Concept
Assay Tech Transfer and Assay Verification
Research Cell Bank
Master / Working Cell Bank
Cell Culture Process Development
Protein Purification and Characterization
Engineering / Pilot Run
cGMP Manufacturing for Clinical Trials

2012 CMO Leadership Awards

For more information, please see our Press Release

Click here to download brochure

The Art of Bioconjugation

Conjugation of monoclonal antibodies and recombinant proteins with other molecules is a specialty of GBI's development and manufacturing groups. Whether the conjugate is a drug toxin (small molecule cancer drugs, plant protein toxins), chelating agents for radio isotopes labeling (diagnostics and therapeutics), adjuvants such as Aluminum Hydroxide-Antibody conjugate, or other antibodies, GBI has the ability to develop and perform them at GMP compliant manufacturing scales for clinical applications. For more information on our Bioconjugation experience, click here.

For more information on developing and manufacturing highly potent Cytotoxic Antibody Drug Conjugates, click here

Biosimilars
An Opportunity

Biologicals represent the fastest growing segment of the pharmaceutical market and over 30 branded biologics with sales in excess of $50 billion are facing patent expirations. That yields a significant business opportunity to develop Biosimilars.
Read more

* The radioisotope image is provided as a courtesy from Ekaterina (Kate) Dadachova, PhD and Arturo Casadevall, MD, PhD as published in Einstein’s dynamic duo of the decade.
Einstein. 2010; Summer / Fall:38-45.